Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian… - Journal of …, 2023 - academic.oup.com
Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients.
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian, C Zhang… - 2023 - cabidigitallibrary.org
Background: Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian, C Zhang… - 2023 - ir.lzu.edu.cn
摘要Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian… - Journal of …, 2023 - academic.oup.com
Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients.
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian… - The Journal of …, 2023 - europepmc.org
Molnupiravir has been considered a promising candidate for COVID-19. Its efficacy and
safety in non-severe COVID-19 patients and the differences between patients with different …
safety in non-severe COVID-19 patients and the differences between patients with different …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian… - The Journal of … - pubmed.ncbi.nlm.nih.gov
Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
M Sun, H Lai, J Huang, J Liu, Y Li, J Tian, C Zhang… - 2023 - ir.lzu.edu.cn
摘要Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …
efficacy and safety in non-severe COVID-19 patients and the differences between patients …